Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty

Rigel Pharmaceuticals (RIGL) has disclosed a new risk, in the Innovation / R&D category.

Rigel Pharmaceuticals may pursue FDA fast track designation for certain product candidates, but investors should recognize that the agency has broad discretion and may decline such requests even when similar products have received the designation. Moreover, even if fast track is granted, it does not guarantee accelerated development, priority review, continued designation, or eventual marketing approval, leaving regulatory timelines and outcomes uncertain.

Overall, Wall Street has a Moderate Buy consensus rating on RIGL stock based on 2 Buys and 2 Holds.

To learn more about Rigel Pharmaceuticals’ risk factors, click here.